Properties and clinical utility of topotecan fluorescence: uses for retinoblastoma.

Jasmine H Francis, Brian P Marr, Paula Schaiquevich, Michael G Kellick, David H Abramson

Journal: The British journal of ophthalmology 2015;99(10):1320-2

PMID: 25926516

Abstract

Topotecan fluoresces when exposed to ultraviolet (UV) light. Our observations with UV light in retinoblastoma cases has allowed us to minimise and manage inadvertent skin contact, guide periocular injections and leakage from such injections and document conjunctival contact after periocular injection in addition to demonstrating the drug in the vitreous after intravitreal injection. The technique is safe, inexpensive and easy to perform.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Address: Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA Department of Ophthalmology, Weill Cornea Medical Center, New York, New York, USA.; Unidad de Farmacocinética Clínica, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.; Pediatric Pharmacy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

DOI: 10.1136/bjophthalmol-2015-306633

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Fluorescein Angiography, Fundus Oculi, Humans, Intravitreal Injections, Retinal Neoplasms, Retinoblastoma, Topoisomerase I Inhibitors, Topotecan, Vitreous Body